BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28271924)

  • 1. Serological biomarkers in triage of FIT-positive subjects?
    Nielsen HJ; Christensen IJ; Andersen B; Rasmussen M; Friis-Hansen LJ; Bygott T; MiCallef J;
    Scand J Gastroenterol; 2017; 52(6-7):742-744. PubMed ID: 28271924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triage for selection to colonoscopy?
    Mertz-Petersen M; Piper TB; Kleif J; Ferm L; Christensen IJ; Nielsen HJ;
    Eur J Surg Oncol; 2018 Oct; 44(10):1539-1541. PubMed ID: 30251643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of advanced colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 1,404 cases.
    Siripongpreeda B; Mahidol C; Dusitanond N; Sriprayoon T; Muyphuag B; Sricharunrat T; Teerayatanakul N; Chaiwong W; Worasawate W; Sattayarungsee P; Sangthongdee J; Prarom J; Sornsamdang G; Soonklang K; Wittayasak K; Auewarakul CU
    BMC Gastroenterol; 2016 Aug; 16(1):101. PubMed ID: 27553627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study.
    Shahidi N; Gentile L; Gondara L; Hamm J; McGahan CE; Enns R; Telford J
    Can J Gastroenterol Hepatol; 2016; 2016():4650471. PubMed ID: 28116286
    [No Abstract]   [Full Text] [Related]  

  • 6. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
    Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
    Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants.
    Aniwan S; Rerknimitr R; Kongkam P; Wisedopas N; Ponuthai Y; Chaithongrat S; Kullavanijaya P
    Gastrointest Endosc; 2015 Mar; 81(3):719-27. PubMed ID: 25708760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden.
    Petersen MM; Kleif J; Jørgensen LN; Hendel JW; Seidelin JB; Madsen MR; Vilandt J; Brandsborg S; Rasmussen JS; Andersen LM; Khalid A; Ferm L; Gawel SH; Martens F; Andersen B; Rasmussen M; Davis GJ; Christensen IJ; Therkildsen C
    Clin Colorectal Cancer; 2023 Jun; 22(2):199-210. PubMed ID: 36878807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-Look Colonoscopies and the Impact on Capacity in FIT-Based Colorectal Cancer Screening.
    Grobbee EJ; Kapidzic A; van Vuuren AJ; van Leerdam M; Lansdorp-Vogelaar I; Looman CW; Bruno MJ; Kuipers EJ; Spaander MC
    Am J Gastroenterol; 2015 Jul; 110(7):1072-7. PubMed ID: 26054624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
    Kelley L; Swan N; Hughes DJ
    Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
    Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
    Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.
    Thomsen MK; Pedersen L; Erichsen R; Lash TL; Sørensen HT; Mikkelsen EM
    Br J Cancer; 2022 May; 126(8):1229-1235. PubMed ID: 35058592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms.
    Chiu HM; Ching JY; Wu KC; Rerknimitr R; Li J; Wu DC; Goh KL; Matsuda T; Kim HS; Leong R; Yeoh KG; Chong VH; Sollano JD; Ahmed F; Menon J; Sung JJ;
    Gastroenterology; 2016 Mar; 150(3):617-625.e3. PubMed ID: 26627608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
    Grobbee EJ; Schreuders EH; Hansen BE; Bruno MJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gastroenterology; 2017 Nov; 153(5):1251-1259.e2. PubMed ID: 28760383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.